Related Experiment Video
Updated: May 7, 2026
Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor
Published on: May 2, 2022
Gastrointestinal stromal tumors: molecular markers and genetic subtypes
Christine M Barnett1, Christopher L Corless, Michael C Heinrich
1Hematology and Medical Oncology, Division of Hematology/Oncology, Portland VA Medical Center, OHSU Knight Cancer Institute, Oregon Health & Science University, Mail Code L586, 3181 Southwest Sam Jackson Park Road, Portland, OR 97239, USA.
Abstract:
Mutation-activated signaling from the KIT and PDGFRA kinases has been successfully targeted in gastrointestinal stromal tumors (GISTs), with subtle differences between the mutations serving to refine prognosis and more precisely tailor therapy. There is a growing understanding of the molecular drivers of GISTs lacking mutations in KIT or PDGFRA, so called wild-type GISTs, further aiding in management decisions. This article provides an overview of all the known molecular subtypes of GIST and provides information about clinical correlates, treatment, and prognosis depending on the subtype.
Insights
Gastrointestinal stromal tumors (GISTs) are increasingly understood. This review details molecular subtypes, guiding GIST treatment and prognosis based on specific mutations or wild-type status.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Gastrointestinal stromal tumors (GISTs) are driven by specific kinase mutations.
- Targeting KIT and PDGFRA mutations has improved GIST therapy.
- Understanding wild-type GISTs is crucial for effective management.
Purpose of the Study:
- To provide a comprehensive overview of GIST molecular subtypes.
- To correlate molecular subtypes with clinical features and prognosis.
- To inform treatment decisions based on GIST molecular profiles.
Main Methods:
- Literature review of GIST molecular alterations.
- Analysis of clinical data associated with GIST subtypes.
- Synthesis of information on treatment strategies and outcomes.
Main Results:
- Detailed classification of known GIST molecular subtypes.
- Identification of prognostic indicators within different subtypes.
- Guidance on subtype-specific therapeutic approaches.
Conclusions:
- Molecular subtyping is essential for personalized GIST treatment.
- Tailoring therapy based on GIST genotype improves patient outcomes.
- Continued research into wild-type GISTs will further refine management.
